{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T21:52:28Z","timestamp":1790805148582,"version":"4.1.0"},"reference-count":157,"publisher":"Elsevier","isbn-type":[{"value":"9780323994019","type":"print"}],"license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100008061","name":"Fundaci\u00f3n Mutua Madrile\u00f1a","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008061","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PI18\/00860"],"award-info":[{"award-number":["PI18\/00860"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PI19\/01128"],"award-info":[{"award-number":["PI19\/01128"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002924","name":"Federaci\u00f3n Espa\u00f1ola de Enfermedades Raras","doi-asserted-by":"publisher","award":["PI21\/00546"],"award-info":[{"award-number":["PI21\/00546"]}],"id":[{"id":"10.13039\/501100002924","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100018937","name":"Bavarian Nordic","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100018937","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/bs.ircmb.2022.03.005","type":"book-chapter","created":{"date-parts":[[2022,5,16]],"date-time":"2022-05-16T08:17:37Z","timestamp":1652689057000},"page":"55-96","source":"Crossref","is-referenced-by-count":11,"title":["Messenger RNA as a personalized therapy: The moment of truth for rare metabolic diseases"],"prefix":"10.1016","member":"78","reference":[{"key":"10.1016\/bs.ircmb.2022.03.005_bb0010","doi-asserted-by":"crossref","first-page":"1357","DOI":"10.1038\/mt.2010.85","article-title":"Targeted delivery of RNAi therapeutics with endogenous and exogenous ligand-based mechanisms","volume":"18","author":"Akinc","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0015","doi-asserted-by":"crossref","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","article-title":"The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs","volume":"14","author":"Akinc","year":"2019","journal-title":"Nat. Nanotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0020","doi-asserted-by":"crossref","first-page":"151","DOI":"10.3727\/000000005783983250","article-title":"Isolated hepatocyte transplantation for Crigler-Najjar syndrome type 1","volume":"14","author":"Ambrosino","year":"2005","journal-title":"Cell Transplant."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0025","doi-asserted-by":"crossref","first-page":"3548","DOI":"10.1016\/j.celrep.2017.11.081","article-title":"Systemic messenger RNA therapy as a treatment for methylmalonic acidemia","volume":"21","author":"An","year":"2017","journal-title":"Cell Rep."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0030","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1016\/j.ebiom.2019.07.003","article-title":"Long-term efficacy and safety of mRNA therapy in two murine models of methylmalonic acidemia","volume":"45","author":"An","year":"2019","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0035","doi-asserted-by":"crossref","first-page":"439","DOI":"10.7326\/0003-4819-142-6-200503150-00010","article-title":"Recommendations for the diagnosis and treatment of the acute porphyrias","volume":"142","author":"Anderson","year":"2005","journal-title":"Ann. Intern. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0040","doi-asserted-by":"crossref","first-page":"5884","DOI":"10.1093\/nar\/gkq347","article-title":"Incorporation of pseudouridine into mRNA enhances translation by diminishing PKR activation","volume":"38","author":"Anderson","year":"2010","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0045","doi-asserted-by":"crossref","first-page":"9329","DOI":"10.1093\/nar\/gkr586","article-title":"Nucleoside modifications in RNA limit activation of 2\u2032-5\u2032-oligoadenylate synthetase and increase resistance to cleavage by RNase L","volume":"39","author":"Anderson","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0050","doi-asserted-by":"crossref","first-page":"404","DOI":"10.1002\/psp4.12301","article-title":"Quantitative systems pharmacology model of hUGT1A1-modRNA encoding for the UGT1A1 enzyme to treat Crigler-Najjar syndrome type 1","volume":"7","author":"Apgar","year":"2018","journal-title":"CPT Pharmacometrics Syst. Pharmacol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0055","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0060","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/j.ymthe.2019.09.018","article-title":"Novel mRNA-based therapy reduces toxic galactose metabolites and overcomes galactose sensitivity in a mouse model of classic galactosemia","volume":"28","author":"Balakrishnan","year":"2020","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0065","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1056\/NEJMoa1913147","article-title":"Phase 3 trial of RNAi therapeutic givosiran for acute intermittent porphyria","volume":"382","author":"Balwani","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0070","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1016\/S1096-7192(02)00171-3","article-title":"High frequency of tetrahydrobiopterin-responsiveness among hyperphenylalaninemias: a study of 1919 patients observed from 1988 to 2002","volume":"77","author":"Bernegger","year":"2002","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0075","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1136\/gutjnl-2019-318269","article-title":"Messenger RNA therapy for rare genetic metabolic diseases","volume":"68","author":"Berraondo","year":"2019","journal-title":"Gut"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0080","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1016\/S0140-6736(10)60961-0","article-title":"Phenylketonuria","volume":"376","author":"Blau","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0085","doi-asserted-by":"crossref","first-page":"e423","DOI":"10.1542\/peds.113.5.e423","article-title":"Living with classical galactosemia: health-related quality of life consequences","volume":"113","author":"Bosch","year":"2004","journal-title":"Pediatrics"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0090","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1111\/bcpt.12586","article-title":"Evaluation of mutual drug-drug interaction within Geneva cocktail for cytochrome P450 phenotyping using innovative dried blood sampling method","volume":"119","author":"Bosilkovska","year":"2016","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0095","doi-asserted-by":"crossref","first-page":"2771","DOI":"10.1001\/jama.284.21.2771","article-title":"Clinical features of and recent advances in therapy for Fabry disease","volume":"284","author":"Brady","year":"2000","journal-title":"JAMA"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0100","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1038\/190576a0","article-title":"An unstable intermediate carrying information from genes to ribosomes for protein synthesis","volume":"190","author":"Brenner","year":"1961","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0105","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1186\/s13023-021-01742-3","article-title":"Health impact of acute intermittent porphyria in latent and non-recurrent attacks patients","volume":"16","author":"Buend\u00eda-Mart\u00ednez","year":"2021","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0110","doi-asserted-by":"crossref","first-page":"6417","DOI":"10.1093\/hmg\/ddv352","article-title":"Human recombinant arginase enzyme reduces plasma arginine in mouse models of arginase deficiency","volume":"24","author":"Burrage","year":"2015","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0115","doi-asserted-by":"crossref","first-page":"700","DOI":"10.1007\/s10545-007-0605-z","article-title":"The response of patients with phenylketonuria and elevated serum phenylalanine to treatment with oral sapropterin dihydrochloride (6R-tetrahydrobiopterin): a phase II, multicentre, open-label, screening study","volume":"30","author":"Burton","year":"2007","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0120","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1523\/JNEUROSCI.0897-16.2016","article-title":"Rescue of the functional alterations of motor cortical circuits in arginase deficiency by neonatal gene therapy","volume":"36","author":"Cantero","year":"2016","journal-title":"J. Neurosci."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0125","doi-asserted-by":"crossref","first-page":"273","DOI":"10.1016\/j.bcmd.2013.01.003","article-title":"Gilbert and Crigler Najjar syndromes: an update of the UDP-glucuronosyltransferase 1A1 (UGT1A1) gene mutation database","volume":"50","author":"Canu","year":"2013","journal-title":"Blood Cells Mol. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0130","doi-asserted-by":"crossref","first-page":"3090","DOI":"10.1038\/s41467-021-23318-2","article-title":"mRNA therapy restores euglycemia and prevents liver tumors in murine model of glycogen storage disease","volume":"12","author":"Cao","year":"2021","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0135","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pediatrneurol.2012.03.016","article-title":"Clinical features and neurologic progression of hyperargininemia","volume":"46","author":"Carvalho","year":"2012","journal-title":"Pediatr. Neurol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0140","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1089\/hgtb.2015.140","article-title":"Expressing transgenes that exceed the packaging capacity of adeno-associated virus capsids","volume":"27","author":"Chamberlain","year":"2016","journal-title":"Hum. Gene Ther. Methods"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0145","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1089\/hum.2010.164","article-title":"Adeno-associated virus serotype 8 gene transfer rescues a neonatal lethal murine model of propionic acidemia","volume":"22","author":"Chandler","year":"2011","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0150","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0968-0004(00)89102-1","article-title":"AU-rich elements: characterization and importance in mRNA degradation","volume":"20","author":"Chen","year":"1995","journal-title":"Trends Biochem. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0155","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1002\/humu.23067","article-title":"Acute intermittent porphyria: predicted pathogenicity of HMBS variants indicates extremely low penetrance of the autosomal dominant disease","volume":"37","author":"Chen","year":"2016","journal-title":"Hum. Mutat."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0160","doi-asserted-by":"crossref","first-page":"121","DOI":"10.2174\/1566524024605798","article-title":"Type I glycogen storage diseases: disorders of the glucose-6-phosphatase complex","volume":"2","author":"Chou","year":"2002","journal-title":"Curr. Mol. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0165","doi-asserted-by":"crossref","first-page":"R526","DOI":"10.1016\/j.cub.2015.05.032","article-title":"Who discovered messenger RNA?","volume":"25","author":"Cobb","year":"2015","journal-title":"Curr. Biol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0170","doi-asserted-by":"crossref","first-page":"8247935","DOI":"10.1155\/2018\/8247935","article-title":"SERPINA1 mRNA as a treatment for alpha-1 antitrypsin deficiency","volume":"2018","author":"Connolly","year":"2018","journal-title":"J. Nucleic Acids"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0175","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1002\/lt.25304","article-title":"Liver transplantation for propionic acidemia and methylmalonic acidemia: perioperative management and clinical outcomes","volume":"24","author":"Critelli","year":"2018","journal-title":"Liver Transpl."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0180","first-page":"CD001919","article-title":"Information provision for stroke survivors and their carers","volume":"11","author":"Crocker","year":"2021","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0185","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1038\/mt.2009.88","article-title":"AAV2\/8-mediated correction of OTC deficiency is robust in adult but not neonatal Spf(ash) mice","volume":"17","author":"Cunningham","year":"2009","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0190","series-title":"GeneReviews","article-title":"Glycogen storage disease type III","author":"Dagli","year":"1993"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0195","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1016\/j.ymthe.2020.10.018","article-title":"Liver injury increases the incidence of HCC following AAV gene therapy in mice","volume":"29","author":"Dalwadi","year":"2021","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0200","doi-asserted-by":"crossref","DOI":"10.3389\/fbioe.2021.628137","article-title":"The limitless future of RNA therapeutics","volume":"9","author":"Damase","year":"2021","journal-title":"Front. Bioeng. Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0205","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1016\/j.tips.2020.08.004","article-title":"Paving the road for RNA therapeutics","volume":"41","author":"Dammes","year":"2020","journal-title":"Trends Pharmacol. Sci."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0210","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1016\/j.jhep.2016.05.012","article-title":"Phase I open label liver-directed gene therapy clinical trial for acute intermittent porphyria","volume":"65","author":"D'Avola","year":"2016","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0215","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ymgme.2007.09.016","article-title":"Increased plasma and tissue guanidino compounds in a mouse model of hyperargininemia","volume":"93","author":"Deignan","year":"2008","journal-title":"Mol. Genet. Metab."},{"issue":"Suppl","key":"10.1016\/bs.ircmb.2022.03.005_bb0220","doi-asserted-by":"crossref","first-page":"S31","DOI":"10.1016\/j.ymgme.2010.01.012","article-title":"Guanidino compound levels in blood, cerebrospinal fluid, and post-mortem brain material of patients with argininemia","volume":"100","author":"Deignan","year":"2010","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0225","doi-asserted-by":"crossref","first-page":"188","DOI":"10.1016\/j.metabol.2018.01.025","article-title":"Hereditary galactosemia","volume":"83","author":"Demirbas","year":"2018","journal-title":"Metabolism"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0230","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1016\/j.ymthe.2019.03.001","article-title":"Improved efficacy in a Fabry disease model using a systemic mRNA liver depot system as compared to enzyme replacement therapy","volume":"27","author":"DeRosa","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0235","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1016\/j.ymgme.2021.07.006","article-title":"Gene therapy for Fabry disease: progress, challenges, and outlooks on gene-editing","volume":"134","author":"Domm","year":"2021","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0240","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1007\/s10038-006-0045-x","article-title":"Molecular analysis of the AGL gene: heterogeneity of mutations in patients with glycogen storage disease type III from Germany, Canada, Afghanistan, Iran, and Turkey","volume":"51","author":"Endo","year":"2006","journal-title":"J. Hum. Genet."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0245","doi-asserted-by":"crossref","DOI":"10.1002\/jimd.12411","article-title":"Acute intermittent porphyria, givosiran, and homocysteine","author":"Fontanellas","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0250","article-title":"Therapeutic RNA interference: a novel approach to the treatment of primary hyperoxaluria","author":"Forbes","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0255","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1097\/MOP.0000000000000422","article-title":"Methylmalonic and propionic acidemias: clinical management update","volume":"28","author":"Fraser","year":"2016","journal-title":"Curr. Opin. Pediatr."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0260","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1007\/s10545-010-9221-4","article-title":"Ovarian function in girls and women with GALT-deficiency galactosemia","volume":"34","author":"Fridovich-Keil","year":"2011","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0265","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.2215\/CJN.14730920","article-title":"Phase 1\/2 study of lumasiran for treatment of primary hyperoxaluria type 1: a placebo-controlled randomized clinical trial","volume":"16","author":"Frishberg","year":"2021","journal-title":"Clin. J. Am. Soc. Nephrol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0270","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1186\/1750-1172-5-30","article-title":"Fabry disease","volume":"5","author":"Germain","year":"2010","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0275","doi-asserted-by":"crossref","first-page":"16051","DOI":"10.1038\/nrdp.2016.51","article-title":"\u03b11-Antitrypsin deficiency","volume":"2","author":"Greene","year":"2016","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0280","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1038\/190581a0","article-title":"Unstable ribonucleic acid revealed by pulse labelling of Escherichia coli","volume":"190","author":"Gros","year":"1961","journal-title":"Nature"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0285","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1089\/hum.2014.126","article-title":"Long-term sex-biased correction of circulating propionic acidemia disease markers by adeno-associated virus vectors","volume":"26","author":"Guenzel","year":"2015","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0290","doi-asserted-by":"crossref","first-page":"366","DOI":"10.1016\/j.ebiom.2018.10.038","article-title":"Association of immune response with efficacy and safety outcomes in adults with phenylketonuria administered pegvaliase in phase 3 clinical trials","volume":"37","author":"Gupta","year":"2018","journal-title":"EBioMedicine"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0295","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.tibtech.2004.04.006","article-title":"Codon bias and heterologous protein expression","volume":"22","author":"Gustafsson","year":"2004","journal-title":"Trends Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0300","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1002\/jimd.12129","article-title":"Pathophysiology of propionic and methylmalonic acidemias. Part 1: complications","volume":"42","author":"Haijes","year":"2019","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0305","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/sj.gt.3302678","article-title":"Complete correction of hyperphenylalaninemia following liver-directed, recombinant AAV2\/8 vector-mediated gene therapy in murine phenylketonuria","volume":"13","author":"Harding","year":"2006","journal-title":"Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0310","doi-asserted-by":"crossref","first-page":"183","DOI":"10.3109\/01913123.2011.601404","article-title":"Glycogen storage diseases: a brief review and update on clinical features, genetic abnormalities, pathologic features, and treatment","volume":"35","author":"Hicks","year":"2011","journal-title":"Ultrastruct. Pathol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0315","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1089\/hum.2008.158","article-title":"Short-term rescue of neonatal lethality in a mouse model of propionic acidemia by gene therapy","volume":"20","author":"Hofherr","year":"2009","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0320","article-title":"Lipid nanoparticles for mRNA delivery","author":"Hou","year":"2021","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0325","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.cell.2009.01.019","article-title":"The many pathways of RNA degradation","volume":"136","author":"Houseley","year":"2009","journal-title":"Cell"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0330","doi-asserted-by":"crossref","first-page":"S77","DOI":"10.1016\/j.ymgme.2018.12.187","article-title":"Liver-targeted AAV gene therapy vectors produced by a clinical scale manufacturing process result in high, continuous therapeutic levels of enzyme activity and effective substrate reduction in mouse model of Fabry disease","volume":"126","author":"Huston","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0335","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.omtm.2021.06.015","article-title":"ImmTOR nanoparticles enhance AAV transgene expression after initial and repeat dosing in a mouse model of methylmalonic acidemia","volume":"22","author":"Ilyinskii","year":"2021","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0340","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.1089\/hum.2019.102","article-title":"Challenges of gene therapy for the treatment of glycogen storage diseases type I and type III","volume":"30","author":"Jauze","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0345","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1016\/j.omtn.2021.05.010","article-title":"mRNA-based therapy in a rabbit model of variegate porphyria offers new insights into the pathogenesis of acute attacks","volume":"25","author":"Jeric\u00f3","year":"2021","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0350","doi-asserted-by":"crossref","first-page":"S80","DOI":"10.1016\/j.ymgme.2018.12.196","article-title":"Liver-directed gene therapy corrects Fabry disease in mice","volume":"126","author":"Jeyakumar","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0355","article-title":"Systemic messenger RNA as an etiological treatment for acute intermittent porphyria","volume":"1","author":"Jiang","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0360","doi-asserted-by":"crossref","first-page":"5339","DOI":"10.1038\/s41467-020-19156-3","article-title":"Dual mRNA therapy restores metabolic function in long-term studies in mice with propionic acidemia","volume":"11","author":"Jiang","year":"2020","journal-title":"Nat. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0365","doi-asserted-by":"crossref","first-page":"7052","DOI":"10.1038\/s41598-020-64017-0","article-title":"Systemic modified messenger RNA for replacement therapy in alpha 1-antitrypsin deficiency","volume":"10","author":"Karadagi","year":"2020","journal-title":"Sci. Rep."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0370","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.immuni.2005.06.008","article-title":"Suppression of RNA recognition by Toll-like receptors: the impact of nucleoside modification and the evolutionary origin of RNA","volume":"23","author":"Karik\u00f3","year":"2005","journal-title":"Immunity"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0375","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkr695","article-title":"Generating the optimal mRNA for therapy: HPLC purification eliminates immune activation and improves translation of nucleoside-modified, protein-encoding mRNA","volume":"39","author":"Karik\u00f3","year":"2011","journal-title":"Nucleic Acids Res."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0380","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/00005792-199201000-00001","article-title":"Prognosis of acute porphyria: occurrence of acute attacks, precipitating factors, and associated diseases","volume":"71","author":"Kauppinen","year":"1992","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0385","doi-asserted-by":"crossref","DOI":"10.1016\/j.nantod.2021.101142","article-title":"Role of nanotechnology behind the success of mRNA vaccines for COVID-19","volume":"38","author":"Khurana","year":"2021","journal-title":"Nano Today"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0390","doi-asserted-by":"crossref","first-page":"87","DOI":"10.4068\/cmj.2020.56.2.87","article-title":"RNA therapy: current status and future potential","volume":"56","author":"Kim","year":"2020","journal-title":"Chonnam Med. J."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0395","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ymgme.2017.01.003","article-title":"Glycogen storage disease type Ia mice with less than 2% of normal hepatic glucose-6-phosphatase-\u03b1 activity restored are at risk of developing hepatic tumors","volume":"120","author":"Kim","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0400","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.addr.2020.12.014","article-title":"Self-assembled mRNA vaccines","volume":"170","author":"Kim","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0405","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nrg3861","article-title":"Emerging roles of tRNA in adaptive translation, signalling dynamics and disease","volume":"16","author":"Kirchner","year":"2015","journal-title":"Nat. Rev. Genet."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0410","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1089\/nat.2018.0740","article-title":"Systemic alanine glyoxylate aminotransferase mRNA improves glyoxylate metabolism in a mouse model of primary hyperoxaluria type 1","volume":"29","author":"Kukreja","year":"2019","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0415","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1038\/gt.2012.99","article-title":"AAV-based gene therapy prevents neuropathology and results in normal cognitive development in the hyperargininemic mouse","volume":"20","author":"Lee","year":"2013","journal-title":"Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0420","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/j.ymgmr.2015.03.001","article-title":"Minimal hepatic glucose-6-phosphatase-\u03b1 activity required to sustain survival and prevent hepatocellular adenoma formation in murine glycogen storage disease type Ia","volume":"3","author":"Lee","year":"2015","journal-title":"Mol. Genet. Metab. reports"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0425","doi-asserted-by":"crossref","first-page":"504","DOI":"10.1016\/S0140-6736(07)61234-3","article-title":"Efficacy of sapropterin dihydrochloride (tetrahydrobiopterin, 6R-BH4) for reduction of phenylalanine concentration in patients with phenylketonuria: a phase III randomised placebo-controlled study","volume":"370","author":"Levy","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0430","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.ymgme.2018.06.002","article-title":"Phenylalanine ammonia lyase (PAL): from discovery to enzyme substitution therapy for phenylketonuria","volume":"124","author":"Levy","year":"2018","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0435","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s40265-019-01079-z","article-title":"Phenylketonuria: current treatments and future developments","volume":"79","author":"Lichter-Konecki","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0440","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1016\/j.omtm.2020.05.034","article-title":"A novel gene therapy approach for GSD III using an AAV vector encoding a bacterial glycogen debranching enzyme","volume":"18","author":"Lim","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0445","doi-asserted-by":"crossref","first-page":"1619","DOI":"10.1039\/C5TB01753J","article-title":"Strategies for modulating innate immune activation and protein production of in vitro transcribed mRNAs","volume":"4","author":"Loomis","year":"2016","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0450","doi-asserted-by":"crossref","first-page":"6077","DOI":"10.1073\/pnas.86.16.6077","article-title":"Cationic liposome-mediated RNA transfection","volume":"86","author":"Malone","year":"1989","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0455","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1542\/pir.2018-0146","article-title":"The glycogen storage disorders","volume":"41","author":"Marion","year":"2020","journal-title":"Pediatr. Rev."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0460","first-page":"57","article-title":"Audit of the use of regular haem arginate infusions in patients with acute porphyria to prevent recurrent symptoms","volume":"22","author":"Marsden","year":"2015","journal-title":"JIMD Rep."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0465","doi-asserted-by":"crossref","first-page":"9330","DOI":"10.1016\/S0021-9258(19)40647-9","article-title":"Modification of RNA by mRNA guanylyltransferase and mRNA (guanine-7-)methyltransferase from vaccinia virions","volume":"250","author":"Martin","year":"1975","journal-title":"J. Biol. Chem."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0470","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.1089\/hum.2019.090","article-title":"A new era for rare genetic diseases: messenger RNA therapy","volume":"30","author":"Martini","year":"2019","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0475","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1093\/qjmed\/hcq117","article-title":"Fabry disease: a review of current management strategies","volume":"103","author":"Mehta","year":"2010","journal-title":"QJM"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0480","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1089\/nat.2015.0537","article-title":"In vitro evaluation of a novel mRNA-based therapeutic strategy for the treatment of patients suffering from alpha-1-antitrypsin deficiency","volume":"25","author":"Michel","year":"2015","journal-title":"Nucleic Acid Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0485","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbagen.2019.129437","article-title":"Progress in the understanding and treatment of Fabry disease","volume":"1864","author":"Miller","year":"2020","journal-title":"Biochim. Biophys. acta. Gen. Subj."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0490","series-title":"GeneReviews","article-title":"Primary hyperoxaluria type 1","author":"Milliner","year":"1993"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0495","doi-asserted-by":"crossref","first-page":"1062","DOI":"10.1016\/j.bbrc.2005.12.105","article-title":"mRNA transfection of dendritic cells: synergistic effect of ARCA mRNA capping with poly(A) chains in cis and in trans for a high protein expression level","volume":"340","author":"Mockey","year":"2006","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0500","doi-asserted-by":"crossref","DOI":"10.1093\/jimb\/kuab063","article-title":"The infinite possibilities of RNA therapeutics","author":"Mollocana-Lara","year":"2021","journal-title":"J. Ind. Microbiol. Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0505","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1124\/dmd.108.021428","article-title":"Expression of UGT1A and UGT2B mRNA in human normal tissues and various cell lines","volume":"36","author":"Nakamura","year":"2008","journal-title":"Drug Metab. Dispos."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0510","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1046\/j.1365-2796.1997.00189.x","article-title":"Acute intermittent porphyria: prevalence of mutations in the porphobilinogen deaminase gene in blood donors in France","volume":"242","author":"Nordmann","year":"1997","journal-title":"J. Intern. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0515","doi-asserted-by":"crossref","first-page":"2541","DOI":"10.3748\/wjg.v13.i18.2541","article-title":"Glycogen storage diseases: new perspectives","volume":"13","author":"Ozen","year":"2007","journal-title":"World J. Gastroenterol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0520","doi-asserted-by":"crossref","first-page":"386","DOI":"10.1038\/ki.2015.97","article-title":"High prevalence of and potential mechanisms for chronic kidney disease in patients with acute intermittent porphyria","volume":"88","author":"Pallet","year":"2015","journal-title":"Kidney Int."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0525","doi-asserted-by":"crossref","first-page":"5711","DOI":"10.1021\/acs.nanolett.7b02664","article-title":"Boosting intracellular delivery of lipid nanoparticle-encapsulated mRNA","volume":"17","author":"Patel","year":"2017","journal-title":"Nano Lett."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0530","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.ymgme.2011.09.022","article-title":"Natural history of propionic acidemia","volume":"105","author":"Pena","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0535","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.ymgme.2018.10.001","article-title":"Hepatocellular carcinoma in acute hepatic porphyrias: a Damocles Sword","volume":"128","author":"Peoc'h","year":"2019","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0540","doi-asserted-by":"crossref","DOI":"10.1016\/j.jhep.2007.03.009","article-title":"Genetics in liver diseases","author":"Pietrangelo","year":"2007","journal-title":"J. Hepatol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0545","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0550","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1016\/j.ymthe.2017.12.024","article-title":"Targeted mRNA therapy for ornithine transcarbamylase deficiency","volume":"26","author":"Prieve","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0555","doi-asserted-by":"crossref","first-page":"1027","DOI":"10.1089\/hum.2006.17.1027","article-title":"Synthetic messenger RNA as a tool for gene therapy","volume":"17","author":"Rabinovich","year":"2006","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0560","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/j.ymgme.2003.08.016","article-title":"Fatal systemic inflammatory response syndrome in a ornithine transcarbamylase deficient patient following adenoviral gene transfer","volume":"80","author":"Raper","year":"2003","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0565","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/jimd.12311","article-title":"A pilot study of neonatal GALT gene replacement using AAV9 dramatically lowers galactose metabolites in blood, liver, and brain and minimizes cataracts in GALT-null rat pups","volume":"44","author":"Rasmussen","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0570","doi-asserted-by":"crossref","first-page":"2200","DOI":"10.1111\/j.1600-6143.2007.01899.x","article-title":"Auxiliary liver transplantation for propionic acidemia: a 10-year follow-up","volume":"7","author":"Rela","year":"2007","journal-title":"Am. J. Transplant."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0575","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.coph.2021.06.001","article-title":"Alpha1-antitrypsin deficiency: new therapies on the horizon","volume":"59","author":"Remih","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0580","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1517\/21678707.2015.1092380","article-title":"Understanding molecular mechanisms in propionic acidemia and investigated therapeutic strategies","volume":"3","author":"Richard","year":"2015","journal-title":"Expert Opin. Orphan Drugs"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0585","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1016\/j.ymthe.2018.01.006","article-title":"G6PC mRNA therapy positively regulates fasting blood glucose and decreases liver abnormalities in a mouse model of glycogen storage disease 1a","volume":"26","author":"Roseman","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0590","doi-asserted-by":"crossref","first-page":"1149","DOI":"10.1182\/blood.V66.5.1149.1149","article-title":"Half-lives of beta and gamma globin messenger RNAs and of protein synthetic capacity in cultured human reticulocytes","volume":"66","author":"Ross","year":"1985","journal-title":"Blood"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0595","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13023-019-1047-z","article-title":"The natural history of classic galactosemia: lessons from the GalNet registry","volume":"14","author":"Rubio-Gozalbo","year":"2019","journal-title":"Orphanet J. Rare Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0600","doi-asserted-by":"crossref","first-page":"1509","DOI":"10.1016\/j.ymthe.2018.03.010","article-title":"A novel amino lipid series for mRNA delivery: improved endosomal escape and sustained pharmacology and safety in non-human primates","volume":"26","author":"Sabnis","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0605","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"MRNA-based therapeutics-developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0610","doi-asserted-by":"crossref","first-page":"870","DOI":"10.1038\/mt.2010.270","article-title":"Phenotypic correction of a mouse model for primary hyperoxaluria with adeno-associated virus gene transfer","volume":"19","author":"Salido","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0615","doi-asserted-by":"crossref","first-page":"228","DOI":"10.3109\/13813455.2014.962547","article-title":"Endogenous galactose formation in galactose-1-phosphate uridyltransferase deficiency","volume":"120","author":"Schadewaldt","year":"2014","journal-title":"Arch. Physiol. Biochem."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0620","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1111\/joim.12750","article-title":"Recurrent attacks of acute hepatic porphyria: major role of the chronic inflammatory response in the liver","volume":"284","author":"Schmitt","year":"2018","journal-title":"J. Intern. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0625","series-title":"GeneReviews","article-title":"Propionic acidemia","author":"Shchelochkov","year":"1993"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0630","doi-asserted-by":"crossref","first-page":"1287","DOI":"10.1007\/s00109-015-1354-3","article-title":"Arginase-1 deficiency","volume":"93","author":"Sin","year":"2015","journal-title":"J. Mol. Med. (Berl)"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.jpeds.2012.11.042","article-title":"UGT1A1 genetic analysis as a diagnostic aid for individuals with unconjugated hyperbilirubinemia","volume":"162","author":"Skierka","year":"2013","journal-title":"J. Pediatr."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0640","doi-asserted-by":"crossref","DOI":"10.3390\/diagnostics11112148","article-title":"Diagnosis and management of inborn errors of metabolism in adult patients in the emergency department","author":"Solares","year":"2021","journal-title":"Diagnostics"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0645","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1016\/j.adnc.2006.08.004","article-title":"Fundamentals of phototherapy for neonatal jaundice","volume":"6","author":"Stokowski","year":"2006","journal-title":"Adv. Neonatal Care"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0650","series-title":"Glycogen Storage Disease","author":"Stone","year":"2021"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0655","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1056\/NEJMra1910234","article-title":"Alpha(1)-antitrypsin deficiency","volume":"382","author":"Strnad","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0660","doi-asserted-by":"crossref","first-page":"774","DOI":"10.1021\/mp100390w","article-title":"In vitro and in vivo mRNA delivery using lipid-enveloped pH-responsive polymer nanoparticles","volume":"8","author":"Su","year":"2011","journal-title":"Mol. Pharm."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0665","series-title":"GeneReviews","article-title":"Arginase deficiency","author":"Sun","year":"1993"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0670","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1038\/mt.2015.103","article-title":"Sequence-engineered mRNA without chemical nucleoside modifications enables an effective protein therapy in large animals","volume":"23","author":"Thess","year":"2015","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0675","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1002\/jimd.12391","article-title":"Dysregulation of homocysteine homeostasis in acute intermittent porphyria patients receiving heme arginate or givosiran","volume":"44","author":"To-Figueras","year":"2021","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0680","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ymthe.2018.12.012","article-title":"Delivery of mRNA therapeutics for the treatment of hepatic diseases","volume":"27","author":"Trepotec","year":"2019","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0685","doi-asserted-by":"crossref","first-page":"21150","DOI":"10.1073\/pnas.1906182116","article-title":"Lipid nanoparticle-targeted mRNA therapy as a treatment for the inherited metabolic liver disorder arginase deficiency","volume":"116","author":"Truong","year":"2019","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0690","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1038\/mt.2010.210","article-title":"Sustained enzymatic correction by rAAV-mediated liver gene therapy protects against induced motor neuropathy in acute porphyria mice","volume":"19","author":"Unzu","year":"2011","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0695","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/gt.2015.64","article-title":"Helper-dependent adenovirus achieve more efficient and persistent liver transgene expression in non-human primates under immunosuppression","volume":"22","author":"Unzu","year":"2015","journal-title":"Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0700","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1038\/s41572-021-00267-0","article-title":"Phenylketonuria","volume":"7","author":"van Spronsen","year":"2021","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0705","doi-asserted-by":"crossref","first-page":"1061","DOI":"10.1089\/hum.2017.150","article-title":"Unraveling the complex story of immune responses to AAV vectors trial after trial","volume":"28","author":"Vandamme","year":"2017","journal-title":"Hum. Gene Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0710","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1002\/lt.22279","article-title":"Liver transplantation for propionic acidemia in children","volume":"17","author":"Vara","year":"2011","journal-title":"Liver Transpl."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0715","doi-asserted-by":"crossref","first-page":"S246","DOI":"10.1016\/j.nmd.2017.06.544","article-title":"TH.O.18\u2014adeno associated vector-based gene therapy strategy for type 3 glycogen storage disease","volume":"27","author":"Vidal","year":"2017","journal-title":"Neuromuscul. Disord."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0720","doi-asserted-by":"crossref","first-page":"1519","DOI":"10.1038\/s41591-018-0209-1","article-title":"Treatment of a metabolic liver disease by in vivo genome base editing in adult mice","volume":"24","author":"Villiger","year":"2018","journal-title":"Nat. Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0725","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1128\/MCB.19.7.4552","article-title":"An mRNA stability complex functions with poly(A)-binding protein to stabilize mRNA in vitro","volume":"19","author":"Wang","year":"1999","journal-title":"Mol. Cell. Biol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0730","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1016\/j.ymgme.2011.10.020","article-title":"Preclinical evaluation of a clinical candidate AAV8 vector for ornithine transcarbamylase (OTC) deficiency reveals functional enzyme from each persisting vector genome","volume":"105","author":"Wang","year":"2012","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0735","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10545-016-9990-5","article-title":"International clinical guideline for the management of classical galactosemia: diagnosis, treatment, and follow-up","volume":"40","author":"Welling","year":"2017","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0740","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1038\/nrd2742","article-title":"Knocking down barriers: advances in siRNA delivery","volume":"8","author":"Whitehead","year":"2009","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0745","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1126\/science.1690918","article-title":"Direct gene transfer into mouse muscle in vivo","volume":"247","author":"Wolff","year":"1990","journal-title":"Science"},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0750","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ymgme.2017.10.002","article-title":"Propionyl-CoA carboxylase\u2014a review","volume":"122","author":"Wongkittichote","year":"2017","journal-title":"Mol. Genet. Metab."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0755","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1002\/jgm.1543","article-title":"Complete restoration of phenylalanine oxidation in phenylketonuria mouse by a self-complementary adeno-associated virus vector","volume":"13","author":"Yagi","year":"2011","journal-title":"J. Gene Med."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0760","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1038\/nbt.3469","article-title":"A dual AAV system enables the Cas9-mediated correction of a metabolic liver disease in newborn mice","volume":"34","author":"Yang","year":"2016","journal-title":"Nat. Biotechnol."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0765","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1038\/mt.2009.250","article-title":"AAV8-mediated gene therapy prevents induced biochemical attacks of acute intermittent porphyria and improves neuromotor function","volume":"18","author":"Yasuda","year":"2010","journal-title":"Mol. Ther."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0770","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.omtm.2020.07.002","article-title":"AAV2\/6 gene therapy in a murine model of Fabry disease results in supraphysiological enzyme activity and effective substrate reduction","volume":"18","author":"Yasuda","year":"2020","journal-title":"Mol. Ther. Methods Clin. Dev."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0775","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1038\/s41439-021-00139-9","article-title":"Novel ARG1 variants identified in a patient with arginase 1 deficiency","volume":"8","author":"Yokoi","year":"2021","journal-title":"Hum. Genome Var."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0780","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1007\/s10545-018-0136-9","article-title":"Biochemical changes and clinical outcomes in 34 patients with classic galactosemia","volume":"41","author":"Yuzyuk","year":"2018","journal-title":"J. Inherit. Metab. Dis."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0785","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.ajhg.2019.02.003","article-title":"Systemic mRNA therapy for the treatment of Fabry disease: preclinical studies in wild-type mice, Fabry mouse model, and wild-type non-human primates","volume":"104","author":"Zhu","year":"2019","journal-title":"Am. J. Hum. Genet."},{"key":"10.1016\/bs.ircmb.2022.03.005_bb0790","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1016\/j.ymthe.2003.11.015","article-title":"AAV2 vector harboring a liver-restricted promoter facilitates sustained expression of therapeutic levels of \u03b1-galactosidase a and the induction of immune tolerance in Fabry mice","volume":"9","author":"Ziegler","year":"2004","journal-title":"Mol. Ther."}],"container-title":["International Review of Cell and Molecular Biology","mRNA-Based Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644822000260?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1937644822000260?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T10:31:20Z","timestamp":1762597880000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1937644822000260"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"ISBN":["9780323994019"],"references-count":157,"URL":"https:\/\/doi.org\/10.1016\/bs.ircmb.2022.03.005","relation":{},"ISSN":["1937-6448"],"issn-type":[{"value":"1937-6448","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]}}}